

Conclusion of Strategic Partnership Agreement with Samsung Bioepis for Commercialization of Biosimilars in Japan

NIPRO CORPORATION (Head Office: Settsu, Osaka; President: Yoshihiko Sano) is pleased to announce that it has entered into a strategic partnership agreement with Samsung Bioepis Co., Ltd. (Head Office: Incheon, Korea; hereinafter “Samsung Bioepis”) for the commercialization of multiple biosimilar products including ustekinumab (brand name: Stelara®*1).



In recent years, biopharmaceuticals have accounted for an increasingly larger share of the prescription drug market. In Japan, the government has made the optimization of healthcare costs through the adoption of biosimilars a formal policy*2, and the role of biosimilars is becoming increasingly significant. Amid these developments, through this strategic partnership, NIPRO will bring to the Japanese market high-quality biosimilars developed and manufactured by Samsung Bioepis, a globally recognized biopharmaceutical company.

Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for commercialization of the medicines in Japan.

By introducing Samsung Bioepis’s high-quality and reliably supplied biosimilars to the Japanese market, NIPRO Group will contribute to expanding treatment options for patients and reducing the burden of healthcare costs.

*1 Stelara is a registered trademark of Johnson & Johnson.

*2 Basic Policy on Economic and Fiscal Management and Reform 2022, For a New Form of Capitalism—Achieving a Sustainable Economy by Harnessing Processes to Overcome Challenges to Drive Growth—

[Comment from Samsung Bioepis]

“This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market. We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world.”

[About Samsung Bioepis]

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology.

For details, please refer to the official website and official social media channel below.

Official Website: ([https:// www.samsungbioepis.com](https://www.samsungbioepis.com))

Official Social Media Channel: X (<https://twitter.com/samsungbioepis>)

LinkedIn (<https://www.linkedin.com/company/samsungbioepis>)

This news release is meant to provide information on NIPRO's corporate activities and an overview of our initiatives to not only the press but also our many stakeholders, including shareholders and investors in a fair and timely manner.

The information about NIPRO products and services included in this release is not intended for use in attracting customers or as medical advice.

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.